The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic Targets

Neuro-Oncology Advances · Published 2026-07-21 · DOI 10.1093/noajnl/vdag189

Free full text

Authors (5)

Christopher M. Stehn, Liangjun Wang, Davis Seelig, Zach Seeman, David A. Largaespada

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Stehn, C., Wang, L., Seelig, D., et al. (2026). The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic Targets. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdag189

Related articles

• Cognitive dysfunction associated with cellular immunotherapy for cancer · Neuro-Oncology Advances · 2026 · Same journal
• The molecular profile of gliomas in adolescents and young adults · Neuro-Oncology Advances · 2026 · Same journal
• Immunogenomic Profiling Reveals Targets for Gene Therapy in Pediatric Brain Tumors · Neuro-Oncology Advances · 2026 · Same journal
• Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis · Neuro-Oncology Advances · 2026 · Same journal
• Mutational signature stratification of recurrent gliomas reveals distinct patterns of genomic traits · Neuro-Oncology Advances · 2026 · Same journal
• Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives · Neuro-Oncology Advances · 2026 · Same journal
• ASL-based Exchange Time Mapping for Differentiation of High-Grade Glioma and Brain Metastases · Neuro-Oncology Advances · 2026 · Same journal
• Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression–free survival · Neuro-Oncology Advances · 2026 · Same journal
• Phase I Trial and Pharmacokinetic Study of Berubicin (RTA 744) in Patients with Recurrent or Refractory High-Grade Gliomas · Neuro-Oncology Advances · 2026 · Same journal
• Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score–matched analysis · Neuro-Oncology Advances · 2026 · Same journal